関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 6-Methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-ylamine | HCID 57512866 | — |
| 反応物 | (2R)-8-chloro-4-methyl-2-phenyl-3,5-dihydro-2H-pyrido[3,2-f][1,4]oxazepine | HCID 57512880 | — |
| 試薬 | Potassium Carbonate | HCID 11430 | — |
| 触媒 | Binap, (A+-)- | HCID 634876 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 溶媒 | Toluene | HCID 1140 | — |
| 生成物 | gamma-Secretase modulator 6 | HCID 49819500 | 100.61% |
反応手順
Charged a round-bottom flask with a mixture of 6-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (5.0 g, 24.48 mmol), (R)-8-chloro-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine (6.73 g, 24.48 mmol), palladium (II) acetate (0.165 g, 0.73 mmol), rac-BINAP (0.762 g, 1.22 mmol), potassium carbonate (5.08 g, 36.72 mmol), and toluene (100 mL). The atmosphere was inerted through consecutive vacuum-nitrogen purge cycles, then heated at 120 °C for 16 hours. HPLC-UV shows a small percentage (<5%) of starting materials remaining. Heating was continued for another 2 hours, then the heating block was removed and the mixture was allowed to cool to room temperature. Added 200 mL dichloromethane and adjusted the pH to 2 with 2.0N aqueous HCl. Separated the phases and basified the aqueous with 1.0N aqueous sodium hydroxide. Extracted with 200 mL DCM, followed by a second extraction with 100 mL DCM. The organics were dried with magnesium sulfate and concentrated by rotary evaporator to yield EN04092-37-001 (10.9 g, 24.63 mmol, 101 %) as an amber-coloured foam.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-0624d5800c4b4df5ab74722e43784236 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|